This 12-week study was a triple blinded, randomized, placebo-controlled trial performed on 29 patients in Iran. 11 patience were randomly assigned the placebo and 18 patients were treated with oral vancomycin (125 mg, four times a day)

The vancomycin group showed a decrease in their alkaline phosphatase, sedimentation rate, GGT, and the Mayo Risk Score. Additionally, and patients’ symptoms including fatigue, pruritus, and diarrhea showed a significant decrease.

The paper’s conclusion states, “This study demonstrated an acceptable efficacy of vancomycin in the treatment of PSC.”